文献速递心律失常

Burst运动负荷试验在儿茶酚胺敏感性多形性室性心动过速中的诊断价值

Burst Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia.
PubMed 文献 · JAMA Cardiol · 2026-01-01

本研究为回顾性队列研究,纳入28例CPVT患者,比较Burst方案与传统Bruce方案的运动负荷试验。Burst方案在71%患者中诱发了更严重的室性心律失常,室性心律失常评分中位数更高(3 vs 1,P < .001),并促使65%患者启动或上调β受体阻滞剂/氟卡尼治疗,未发生不良安全事件。

要点

  • Burst方案较Bruce方案在CPVT患者中诱发更严重室性心律失常(评分3 vs 1)。
  • Burst试验阳性促使65%患者启动或上调β受体阻滞剂/氟卡尼治疗。
  • Burst方案未观察到不良安全事件,低风险且常提供诊断信息。

核心结论

  • 在CPVT患者中,Burst运动负荷试验方案较Bruce方案检测到更重负荷和更严重的室性心律失常,常促使治疗升级,且未观察到安全事件。

研究设计与样本

  • 回顾性队列研究,来自加拿大温哥华2个三级转诊中心,2017年5月至2024年5月收集数据。
  • 筛查38例患者,最终纳入28例连续接受Bruce和Burst运动试验且有可获取轨迹和至少1项试验诊断表型的患者。
  • 队列包括13例女性(46%)和18例先证者(64%),其中23例(82%)携带致病性RYR2变异。

主要发现

  • Burst方案在20/28例患者(71%)中诱发了更严重的室性心律失常。
  • Burst试验的室性心律失常评分中位数(IQR)为3(2-4),Bruce试验为1(1-2),P < .001。
  • Burst试验结果促使13例患者(65%)启动β受体阻滞剂或氟卡尼或剂量上调。
  • 未发生不良安全事件。

关键数值与推荐

  • 室性心律失常评分范围0(无室性早搏)至4(非持续性室性心动过速)。
  • Bruce试验时中位(IQR)年龄为19.9(14.8-33.9)岁,Burst试验时为21.0(16.1-35.5)岁。
  • Bruce和Burst试验间隔中位(IQR)为1.3(0.6-2.0)年,所有Burst试验均在等效或强化治疗下进行。

临床怎么用

  • 在CPVT患者常规护理中纳入Burst方案运动负荷试验风险低且常提供诊断信息。
  • Burst方案可揭示Bruce方案可能遗漏的室性心律失常,从而指导治疗升级。

局限性

  • 回顾性队列研究,样本量较小(28例),来自2个中心。
  • Bruce和Burst试验间隔中位1.3年,且Burst试验均在等效或强化治疗下进行,可能影响比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare inherited arrhythmogenic syndrome in which exercise stress testing is the primary method for provoking adrenergically mediated ventricular arrhythmias. Traditional exercise testing protocols, such as the Bruce protocol, may lack sensitivity, leading to missed diagnoses and undertreatment, whereas early pilot data suggest that a sudden high-intensity Burst protocol may better unmask arrhythmias. OBJECTIVE: To evaluate the diagnostic yield and therapeutic impact of the Burst exercise stress testing protocol compared with the traditional Bruce protocol in CPVT. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included pediatric and adult patients evaluated for CPVT at 2 tertiary referral centers in Vancouver, British Columbia, Canada. Data were collected from May 2017 through May 2024, and data analysis was performed from May 2024 through April 2025. Of 38 screened patients, 28 were included who had undergone consecutive Bruce and Burst exercise tests, with available tracings and a diagnostic phenotype on at least 1 test. Arrhythmia severity was scored using the Ventricular Arrhythmia Score. EXPOSURE: Type of exercise stress testing protocol (Bruce vs Burst). MAIN OUTCOMES AND MEASURES: The main outcome was the Ventricular Arrhythmia Score (ranging from 0 = no premature ventricular contractions to 4 = nonsustained ventricular tachycardia). Other outcomes included changes in pharmacologic therapy and adverse events. RESULTS: The cohort included 13 female patients (46%) and 18 probands (64%), including 23 (82%) with a causative RYR2 variant. Median (IQR) age at testing was 19.9 (14.8-33.9) years for Bruce testing and 21.0 (16.1-35.5) years at Burst testing. Bruce and Burst exercise tests were performed a median (IQR) of 1.3 (0.6-2.0) years apart, with all Burst tests performed on equivalent or intensified therapy. The Burst protocol provoked more severe arrhythmias in 20 of 28 patients (71%) with a higher median (IQR) Ventricular Arrhythmia Score (3 [2-4] vs 1 [1-2]; P < .001). These findings prompted β-blocker or flecainide initiation or dose escalation in 13 patients (65%). No adverse safety events occurred. CONCLUSIONS AND RELEVANCE: In this cohort study, the Burst exercise stress testing protocol detected a greater burden and severity of ventricular arrhythmias than the Bruce protocol in patients with CPVT, frequently prompting treatment escalation without observed safety concerns. These data suggest that incorporating Burst protocol exercise stress testing into the routine care of patients with CPVT is low risk and often informative.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Naderi B, Li COY, Davies B, et al. Burst Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia. JAMA Cardiol. 2026. PMID: 41949873. doi:10.1001/jamacardio.2026.0384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。